April 27 set for Guidant shareholder vote on Johnson & Johnson deal:
This article was originally published in Clinica
Guidant's shareholders will vote on the proposed merger of the company with Johnson & Johnson on April 27. All shareholders on record as of March 21 will be eligible to vote on the $25.4bn ($23.9bn net) deal, which was announced in December 2004. The transaction is still being scrutinised by the US and European antitrust authorities.
You may also be interested in...
Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.
Paracetamol, acetylcysteine and loperamide among list of OTC drugs deemed "essential" by Spain in the fight against coronavirus.
Mylan, in partnership with Indian firm Lupin, will be looking to rival Biogen and Sandoz by introducing an etanercept biosimilar in European markets following a positive opinion by the EMA’s CHMP on Mylan's application.